Trial record 1 of 1 for: RECOMBINANT HUMAN ARGINASE 1 (rhArg1) IN PATIENTS WITH ADVANCED, ARGININE AUXOTROPHIC SOLID TUMORS: DOSE ESCALATION, SAFETY AND PK/PD

Previous Study | Return to List | Next Study

Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02285101

Recruitment Status : Completed

First Posted : November 6, 2014

Last Update Posted : April 24, 2020

Sponsor:

Collaborator:

Oncotherapeutics

Information provided by (Responsible Party):

Bio-Cancer Treatment International Limited

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	February 2019
Actual Study Completion Date :	February 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

De Santo C, Cheng P, Beggs A, Egan S, Bessudo A, Mussai F. Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma. J Hematol Oncol. 2018 May 18;11(1):68. doi: 10.1186/s13045-018-0612-6.

To Top